Optimizing the supply of whole blood-derived bioproducts through the combined implementation of cryopreservation and pathogen reduction technologies and practices: An overview

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61383082%3A_____%2F20%3A00000918" target="_blank" >RIV/61383082:_____/20:00000918 - isvavai.cz</a>

Alternative codes found

RIV/60162694:G44__/20:00555877 RIV/68407700:21460/20:00349465

Result on the web

<a href="https://pubmed.ncbi.nlm.nih.gov/32165117/" target="_blank" >https://pubmed.ncbi.nlm.nih.gov/32165117/</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.transci.2020.102754" target="_blank" >10.1016/j.transci.2020.102754</a>

Result language

angličtina

Original language name

Optimizing the supply of whole blood-derived bioproducts through the combined implementation of cryopreservation and pathogen reduction technologies and practices: An overview

Original language description

The essential historical knowledge and expertise developed over the past 5-6 decades on the safety / efficacy of conventional blood components therapy by blood transfusion establishments have guided the development of validated methods which have ensure optimal safety margins for frozen blood and its bioproducts with or even without pathogen reduction. Newer generations of pathogen reduced frozen red blood cell, plasma and platelet products and the standardised and safer pooling of human platelet lysate are now become available for potential clinical use. These types of whole blood-derived bioproducts not only reduce the risk of transmission of range of pathogenic blood-borne pathogen. As cryopreservation can be combined with PRT without significantly compromising in vitro quality characteristics or physiological capabilities, it allows us to maximize the available inventory of these blood products in both civil and military trauma settings. The main objective of this overview is to update readers and scientific / medical communities of the various building blocks needed to optimally grantee the pathogen safety of whole blood-derived bioproducts, with minimal untoward events to the recipients. While this is an emerging area, we are seeing the numerous potential opportunities that cryopreservation and pathogen inactivation can have on the transfused patient outcomes. This manuscript is informed by recent publications on this topic.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30205 - Hematology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2020

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

TRANSFUSION AND APHERESIS SCIENCE

ISSN

1473-0502

e-ISSN

—

Volume of the periodical

59

Issue of the periodical within the volume

2

Country of publishing house

GB - UNITED KINGDOM

Number of pages

3

Pages from-to

1-3

UT code for WoS article

000538121900026

EID of the result in the Scopus database

—